Part One, Novartis: A Strategic Game-Theory Analysis of Why the Best-Informed Suitor Cannot Sit Still, Across the Partner That Already Knows the Value, the Patent Cliff That Sets the Clock, and the Multi-Tissue Engine Whose Price Looks Steep Only Until It Is Measured Against the Problem It Solves.
Robert Toczycki, JD, MBA
bioboyscout.com
bioboyscout@gmail.com
847.227.7909
X: @BioBoyScout
About This Series
This is the first of three connected papers. Each imagines how one large pharmaceutical company, Novartis here, then Lilly, then Roche, would approach acquiring Arrowhead Pharmaceuticals, and how Arrowhead would respond. The exercise is built entirely on the public record: each company’s actual acquisition history, its publicly stated strategy, the way it has behaved in past deals under its current leadership, and the public facts about Arrowhead. It is a thought experiment about strategic mechanics, not a prediction, and not a claim that any deal is under discussion. I have no knowledge of any such discussions. The purpose is to understand how a deal like this would actually unfold, and why the presence of three suitors rather than one changes everything. The three papers escalate: this one looks at a single acquirer’s calculus; the later two show how the suitors, aware of one another, reshape each other’s choices until the most disciplined of them is forced into a move it never wanted to make.
Executive Summary
Of the three companies most likely to want Arrowhead, Novartis is the one that already knows it from the inside. The two companies are partners, joined by a licensing agreement, which means Novartis has worked directly with Arrowhead’s science and understands the platform more intimately than a cold outside bidder ever could. That familiarity is the theme of this paper, because it cuts in two directions at once. It makes Novartis the suitor best equipped to recognize what Arrowhead is worth, and the suitor least able to pretend it is worth little.
Novartis also has a clear and documented reason to want it. The company is facing a genuine wave of patent expirations, it has built its entire recent dealmaking strategy around filling that gap, it remains one of the few large pharmaceutical companies still committed to neuroscience, and in October 2025 it paid roughly $12 billion for Avidity Biosciences, a company whose core technology delivers RNA into tissue using the same cell-surface docking point, and the same delivery approach, that Arrowhead uses, applied to a different and easier tissue. Novartis has, in other words, already written a $12 billion check to validate the precise class of technology Arrowhead is built on. That single fact frames everything that follows.
This paper lays out why Arrowhead fits Novartis, how Novartis actually does deals (a stated philosophy of disciplined, small acquisitions that coexists with a proven willingness to pay up when the strategic fit is right), how a rational Novartis would approach Arrowhead given that history, and how Arrowhead, holding the leverage described elsewhere in this series, would respond. It closes on the dilemma that sets up the rest of the trilogy: the partner who knows the value best is also the partner who can be outbid by a rival with deeper pockets, and that possibility is what turns a patient strategy into an urgent one.
I. Why This Is a Deal Worth War-Gaming
Before turning to Novartis specifically, it is worth being clear about why three of the largest companies in the industry would want Arrowhead at all, because the whole series rests on it. The short version, argued at length across the other BioBoyScout papers, is that Arrowhead is not a single drug or even a collection of drugs. It is a platform: a delivery system that has been extended into tissue after tissue, that generates new drug programs on a predictable cadence, and that has now produced an approved product and owns its own commercial-scale manufacturing. A company that acquires Arrowhead is not buying a pipeline. It is buying the machine that makes the pipeline.
The reach of that machine is the part most easily underestimated. Arrowhead’s platform already operates in the clinic across the liver, muscle, lung, fat tissue, and the central nervous system, and the map is still growing: the company has extended the platform to two further tissues, an ocular program targeting the eye for glaucoma, with deep gene knockdown already demonstrated in non-human primates, and an early program aimed at the heart muscle itself. Seven tissues, five in the clinic and two advancing behind them, and the roadmap extends further still. An acquirer is therefore not buying three wholly owned franchises, the cardiometabolic, obesity, and central nervous system programs that are visible today. It is buying the exclusive right to whatever the platform generates next, in every tissue it has reached and every tissue it will reach. That distinction changes the nature of the asset. A pipeline is a finite list of programs that can be counted and valued. A platform that reaches across the body is an open-ended generator of programs, many in therapeutic areas the acquirer may not even occupy yet, and each one arriving with a choice attached: enter that area to develop and sell the drug, or license it out to someone who already operates there. Owning Arrowhead means owning that stream of future choices, which is worth far more than the three franchises on the table today, and is the part of the value that a program-by-program tally can never capture.
There is a second engine sitting on top of the first, and it is the one most likely to define the next decade. Every molecule Arrowhead has designed, synthesized, and tested across fifteen years and all of those tissues has produced data: a proprietary record of which sequences, chemistries, and delivery approaches work, and, more valuably, which ones fail. That record cannot be bought, scraped, or licensed, because it does not exist anywhere outside Arrowhead, and the failures, the most useful part for designing the next molecule, were never published. As a separate analysis in this body of work argues at length, this is the real moat in an age of artificial intelligence: the models that turn data into faster discovery are increasingly available to everyone, but the proprietary data that makes those models useful is available to no one else. A company that pairs that dataset with a serious internal artificial-intelligence capability, which Arrowhead is now building, does not simply make drugs; it makes drugs faster, cheaper, and with a higher hit rate than a competitor starting without the data, and it improves at doing so with every new experiment.
The two engines compound each other, and that interaction is what an acquirer is truly buying. Because the underlying biology of the platform is modular, what Arrowhead learns designing a liver drug informs the next muscle drug, and what it learns in the lung informs the next program in the eye or the heart. The data advantage therefore does not merely deepen within one tissue; it broadens across every tissue the platform reaches, so that each expansion of the map makes the discovery engine smarter everywhere at once. A buyer acquiring Arrowhead is acquiring not a fixed rate of drug output but an accelerating one, a machine that produces more programs across more tissues, and gets better and faster at producing them the longer it runs. That is the difference between a valuable asset and a compounding one, and it is the part of Arrowhead’s value least visible on any pipeline chart and least possible for a rival to reconstruct.
That distinction matters enormously for the largest companies right now, because they are all bracing against the same generational wave of patent expirations late in this decade. They can replace lost revenue slowly and expensively by buying one drug at a time, or they can buy a platform that generates drugs for years. A validated, multi-tissue platform is the rare asset that addresses the replacement problem structurally rather than one molecule at a time, which is exactly why it commands attention from companies that can normally fill their pipelines with bolt-on purchases. How sharply that logic applies to Novartis in particular is the subject of a later section.
There is a second reason these companies cannot be indifferent to Arrowhead, and it is the engine of this entire series. Whatever Arrowhead is worth to any one of them, it is worth more once a rival might take it instead. A platform that strengthens whoever owns it also weakens whoever lets a competitor own it, and in a small field of giants chasing the same therapeutic areas, that second effect can matter as much as the first. The multi-tissue reach just described makes this sharper still, because a rival who lets a competitor buy Arrowhead is not ceding three programs; it is ceding an engine that will keep producing drugs across tissue after tissue for years, some of which may land in the loser’s own core franchises. Worse, it is ceding the one advantage no amount of money can rebuild, the irreplaceable data accumulated over fifteen years, and handing a rival a discovery engine that only widens its lead the longer it runs. The question, then, is never simply what Arrowhead is worth to Novartis. It is what Arrowhead is worth to Novartis given that Lilly and Roche are looking at the same board. This first paper sets that aside to focus on Novartis alone, and the later two bring the rivals back in. The reader should keep them in the corner of the eye throughout.
There is a name for this situation, and it comes from chess. When I was a kid learning the game, I was taught a small piece of etiquette that has since fallen out of use. When you attacked your opponent’s queen, you were supposed to announce it, the way you announce check on the king, by saying “en garde.” The phrase is obsolete now; modern players are expected to notice their own queen is under threat without being told. I have always been fond of it anyway, and it turns out to be the right phrase for this series, because an earlier paper in this body of work argued that, on the board of biopharmaceutical acquisitions, Arrowhead is the queen, the single most valuable and most decisive piece in play. This trilogy is the story of three players closing in on that queen. “En garde” is the warning that the attack has begun, and Novartis, as we will see, is the first player on the board with reason to hear it.
II. Why Arrowhead Fits Novartis
Novartis is an unusually natural fit for Arrowhead, on more fronts than any casual observer would guess, and the fit is documented rather than speculative. Start with neuroscience. As large pharmaceutical companies retreated from brain diseases over the past decade, frustrated by repeated clinical failures, Novartis stayed. It is one of the few giants that kept building in neuroscience, and it has been explicit that genetically defined neurological diseases with high unmet need are central to its long-term strategy. Arrowhead’s lead central nervous system program, a tau-lowering therapy for Alzheimer’s and other tauopathies, the family of brain diseases driven by buildup of the tau protein, sits squarely in that priority.
The cardiovascular fit is just as real, and on close inspection it is the sharpest of all, because it is not merely additive but defensive. Novartis built a major cardiovascular franchise, and one of its anchors is now facing the patent expiration discussed in the next section. Less obvious, and more pointed, is that Novartis owns Leqvio, the first and only approved gene-silencing therapy, an siRNA drug, for lowering LDL, the so-called bad cholesterol. Novartis paid nearly $10 billion to acquire it and has worked hard to turn it into a multibillion-dollar blockbuster. Leqvio works by silencing a single gene, called PCSK9, that controls cholesterol. Arrowhead now has in the clinic a dual-target therapy, its dimer program, designed to silence that same PCSK9 gene and a second one, APOC3, in a single molecule, lowering both LDL cholesterol and triglycerides, a second type of blood fat, at once. In the large population of patients who have elevated levels of both, a single Arrowhead injection could do what Leqvio does and cover a second axis of cardiovascular risk that Leqvio does not touch.
That is not a distant or speculative threat, and the reason is the part most worth understanding. Arrowhead’s dimer is early, in a Phase 1 and 2a study, but early does not mean unproven here, for two reasons. First, the platform’s defining strength is the reliability with which it knocks down its genetic target; across a deep liver-focused franchise, with four separate programs already advanced into Phase 3, Arrowhead has consistently achieved the deep, durable target silencing its technology is built to produce. Second, the dimer’s two targets are not gambles. PCSK9 is validated by Leqvio itself and by the approved antibody drugs; APOC3 is validated by Arrowhead’s own first commercial product. The dimer is therefore not reaching for unproven biology; it is combining two clinically established targets, in the liver, where Arrowhead’s delivery is most validated. The mechanism risk is unusually low, which means the threat to Leqvio is unusually credible.
For Novartis, this transforms the cardiovascular fit into something more urgent than opportunity. The other suitors would see Arrowhead's cardiometabolic pipeline as a promising set of assets. Novartis would see, more sharply than anyone, the program most likely to leapfrog the cholesterol-lowering franchise it acquired at great cost and has worked for years to establish. The company that understands the platform best is also the incumbent with the most to lose if a rival, rather than Novartis, ends up owning the drug that could leapfrog Leqvio. Owning Arrowhead would let Novartis defend its hard-won leadership in cardiovascular RNAi by acquiring the next generation of it, rather than watching that next generation arrive in a competitor's hands. Arrowhead's approved cardiometabolic product and the broader pipeline behind it only deepen a fit that, on this front, Novartis would find difficult to ignore.
Then there is the platform itself, and here Novartis’s history with Arrowhead runs deeper than almost anyone remembers. Novartis worked in RNA interference for more than a decade and built its own portfolio in the field. In 2015, amid an industry-wide retreat from the technology, Novartis judged that portfolio not worth keeping and sold the whole of it to Arrowhead: the underlying patents and the freedom they gave Arrowhead to operate, an exclusive license to its other RNAi patents, three preclinical candidates, and an assignment of its own license to foundational Alnylam intellectual property covering thirty gene targets. The price was about $35 million. Part of the ground Arrowhead now stands on, in other words, Novartis once owned and handed over for a sum neither company would notice today. A company that once gave a competitor part of its own foundation understands, better than any outsider could, what that foundation has become.
What Novartis did next is the part that should sharpen its attention now. Four years after walking away, it paid $9.7 billion for The Medicines Company to acquire inclisiran, the cholesterol-lowering RNAi medicine now sold as Leqvio, re-entering the field for nearly three hundred times what it had been paid to leave it. A company that has lived that whole arc, underestimating the modality, selling its position cheaply, then paying billions to buy back in, does not need convincing what a mature RNAi platform is worth. It has already paid, twice, to learn. There is a closing irony in it as well: the company Novartis sold its RNAi assets to in 2015 is the same company whose dimer now threatens the very franchise it bought to return. Arrowhead is not a stranger to Novartis. It is, in part, what Novartis let go, grown into the rival best positioned to leapfrog its expensive way back in.
The obesity angle is the most interesting, because it is the one where Novartis has deliberately stayed out. Unlike most of its peers, Novartis chose not to chase the GLP-1 weight-loss market, and its leadership has said plainly that it does not regret skipping what it views as a crowded field of similar drugs. That stance is not indifference to obesity; it is a refusal to enter with a me-too. It actually makes a differentiated, non-GLP-1 mechanism more interesting to Novartis, not less, because a genuinely novel approach is the only kind of obesity entry consistent with its stated reluctance to join the herd. Arrowhead’s obesity programs, which work through mechanisms entirely different from the GLP-1 drugs, are precisely that kind of differentiated entry. The fit, taken together, spans neuroscience, cardiovascular, the RNA platform, and even the one major area Novartis has pointedly avoided.
These are the fits visible today, and the platform’s reach described earlier means they are not the end of it. Even a company as broad as Novartis does not operate everywhere the platform does, so owning Arrowhead would mean inheriting a stream of future programs in areas where Novartis has no franchise at all, each one posing the same build-or-license question. Here Novartis is better placed than most of its rivals: one of the broader footprints in the industry can absorb that demand more comfortably than a focused buyer could. The reach is still an obligation as much as a prize, but it is one Novartis is unusually equipped to carry, which only deepens the fit rather than complicating it.
III. The Cliff Novartis Is Actually Facing
The reason Novartis is a motivated buyer, and not merely an interested one, is a patent cliff that is real, large, and already arriving. This is not speculation; it is the stated driver of the company’s own strategy. Entresto, the heart-failure drug that has been one of Novartis’s biggest sellers, lost United States market exclusivity in 2025 and loses European exclusivity in 2026. It is not alone. Several other major Novartis products, including Xolair, Cosentyx, and others, face loss of exclusivity before the end of the decade, and the company saw a trio of big-selling drugs lose protection in the final quarter of 2025 alone. The exposed revenue runs well into the tens of billions of dollars.
Novartis has been candid that this is the problem its dealmaking is meant to solve. Its leadership frames acquisitions explicitly as building growth for the 2030-and-beyond period, the years when the cliff bites hardest. By its own account, the company has executed more than thirty strategic deals over the past two years, capped by the roughly $12 billion agreement to acquire Avidity, all aimed at strengthening the pipeline against the revenue the expirations will take away. This is a company shopping with a deadline, and a deadline changes how a buyer behaves. It makes waiting expensive and it makes a structural solution, a platform that generates revenue for years rather than a single replacement drug, especially attractive.
For Arrowhead, this is what shapes Novartis’s urgency. The cliff is the reason Novartis cannot treat the company as a small bolt-on to consider at leisure: the same clock running against its franchises is the clock that rewards moving decisively on a structural fix rather than waiting. That urgency also reframes how Novartis would weigh the price.
There is a further point here that reframes the entire question of price, and it deserves to be stated plainly, because it is the consideration most likely to push a disciplined buyer past its stated limits. The price of acquiring Arrowhead looks large only when it is measured against the wrong thing. Measured against today’s pipeline or today’s revenue, a record premium looks expensive. Measured against the problem it solves, the tens of billions of dollars in exposed revenue that the cliff will strip away, and the decade of new programs a working platform would generate to replace it, that same premium can look like the cheapest available answer to the most expensive problem Novartis has. A single replacement drug solves one year of the cliff; a platform that produces drugs across many tissues for years solves the structural problem itself. If Arrowhead’s platform delivers, and that conditional governs everything in this series, the buyer who wins it will not be remembered as the company that overpaid. It will be remembered as the company that bought, at a price that seemed steep for a single afternoon, the engine that carried it through its hardest decade. The right way to judge the number is not against what Arrowhead earns now, but against what it would cost Novartis to face the cliff without it.
There is something this defensive framing leaves out, though, and it is the part Novartis would feel most keenly. A company facing the largest patent wave in its history is a company on defense, managing decline and patching revenue holes one deal at a time. What Arrowhead offers Novartis is not merely a patch but a way off defense entirely. A platform that generates new programs across the body on its own cadence does not just replace what the cliff takes away; it changes the kind of company Novartis is, from one bracing against expirations into one with a self-renewing source of growth it owns and controls. For a management team that has spent years explaining how it intends to survive the cliff, the chance to stop talking about survival and start talking about expansion is worth more than any single figure can express.
That is the version of this deal Novartis would want, not the grim arithmetic of cliff-filling but the reinvention its recent dealmaking has been reaching toward. Arrowhead would let Novartis enter the 2030s not as a company that weathered its hardest decade, but as one that used the decade to remake itself around the genetic-medicine engine it has been assembling piece by piece and could instead own whole. The cliff is the reason Novartis must act. The platform is the reason it would want to. A buyer pushed by a problem and pulled by a prize is the most motivated buyer there is, and that pairing, the need underneath and the ambition on top, is what would carry Novartis past the limits it sets for itself.
IV. How Novartis Actually Does Deals
To understand how Novartis would approach Arrowhead, look at how Novartis has actually behaved, because its real record complicates its stated philosophy in a revealing way. The stated philosophy is discipline. Novartis leadership has said repeatedly that its strategy is bolt-on acquisitions, that it is best when it sticks to deals in the low-single-digit-billions range, often below $2 billion, and that over many years it has done only a small handful of larger deals. The public message is consistent: small, frequent, disciplined, science-first.
The revealed behavior is more interesting, because Novartis has shown that when an asset is strategically important enough, the discipline yields. In October 2025 it agreed to acquire Avidity Biosciences for roughly $12 billion, many times its stated comfort range, to gain a late-stage RNA pipeline for neuromuscular disease. The company justified the price by pointing to multibillion-dollar opportunities with launches planned before 2030, the cliff-replacement logic in action. The honest reading of Novartis, then, is not that it is cheap. It is that it is disciplined by default and willing to stretch dramatically when an asset hits the center of its strategy. The stated range describes the average deal; it does not describe the ceiling, and the ceiling is far higher than the rhetoric suggests.
The Avidity deal is not just evidence that Novartis will pay up. It is almost a blueprint for an Arrowhead acquisition, because the technology is closely related. Avidity’s platform delivers its RNA medicine into tissue by attaching it to an antibody that latches onto a specific docking point on the cell surface, the transferrin receptor, the same receptor, and the same attach-and-deliver concept, that Arrowhead uses to carry its tau therapy into the brain. The two are not identical, and the difference favors Arrowhead. Avidity delivers to muscle; Arrowhead crosses the blood-brain barrier, which is a substantially harder delivery problem, and one Arrowhead is solving across multiple tissues rather than one. Novartis, in other words, has already paid $12 billion to own a transferrin-receptor-targeted delivery platform aimed at the easier tissue. Arrowhead applies the same fundamental approach to the harder one, with a wider footprint across the body and an approved product already in hand. The most expensive part of evaluating a novel platform is conviction that the mechanism works and the price is justified, and Novartis has already reached that conviction once, with its checkbook. That makes Arrowhead not a leap for Novartis but a logical next step along a path it has already chosen to walk.
Willingness, though, is not the same as capacity, and on capacity Novartis is the most constrained of the three suitors. Working from its own filings, Novartis ended 2025 with net debt near $22 billion, annual free cash flow of roughly $18 billion, and operating earnings before depreciation and amortization on the order of $24 billion. Prudent borrowing alone might fund somewhere around $50 to $75 billion of an acquisition; reaching $100 billion would require Novartis to combine aggressive borrowing with a substantial issuance of its own stock, and stretching toward $140 to $150 billion, very roughly $900 to $970 a share, would pile real balance-sheet strain on top of that. Novartis can finance a transaction of this size, since cash-and-stock deals are routine, but it, alone among the three, would feel the strain of a top-of-range price most acutely, because its balance sheet is the tightest and its need the most pressing. These are estimates derived from public filings, not precise thresholds, yet the shape is clear: Novartis is the bidder most motivated to win and least equipped to prevail in a long contest. That combination argues for bidding early and firmly rather than waiting, because every additional round of an auction works against the participant with the least room left to maneuver.
V. The Novartis Playbook for Arrowhead
Put the fit, the cliff, and the deal style together, and a characteristic Novartis approach to Arrowhead takes shape. It would be the approach of a disciplined buyer who already knows the asset, faces a deadline, and has a proven willingness to pay for the right platform, which is a specific and somewhat constrained set of moves.
The defining feature is that Novartis cannot play the usual opening move of a platform acquisition, which is to suppress the price by professing uncertainty about whether the technology works. Novartis has already removed its own ability to make that argument, several times over. It is Arrowhead's existing partner, so it has worked with the science directly and cannot credibly claim to doubt it. It has publicly paid $12 billion for a closely related mechanism, and it already owns Leqvio, an approved gene-silencing medicine of exactly this kind, so it cannot pretend the technology class is unproven. A buyer who has partnered on the science, validated the mechanism class with its own money, and already sells an approved drug built on it has forfeited the argument that the platform might not work. This is the paradox of the informed acquirer: familiarity that helps it recognize value also strips away its ability to argue that value down by feigning doubt.
A rational Novartis would therefore more likely compete on relationship and certainty than on outright price suppression. Its natural pitch to Arrowhead would emphasize fit and trust: we already work together, we understand your platform, we have the neuroscience and cardiovascular and RNA infrastructure to make the most of it, and we can offer a clean, certain transaction without the friction of educating a less-informed buyer. The existing partnership is Novartis’s strongest card, because it offers Arrowhead a known quantity. This does not mean Novartis would negotiate softly. An informed buyer that cannot plausibly claim the asset is weak can still bargain hard on everything else, the timing of its approach, the structure of the consideration, the use of milestones and contingent payments to bridge a gap on headline value. The point is narrower: Novartis cannot win on the argument that the platform might fail, so it must compete on other ground. The place it would most try to gain an edge is timing. As the partner with the closest view, Novartis is well positioned to judge when to move relative to Arrowhead’s pivotal data, and a disciplined buyer would prefer to act before a positive readout sends the price sharply higher rather than after.
VI. What Novartis Knows About the Other Two
No acquirer evaluates Arrowhead in isolation, and Novartis least of all, because its inside knowledge of the platform is also inside knowledge of how badly a rival would want it. The same diligence that tells Novartis what Arrowhead is worth tells it what Lilly or Roche would gain by taking it, and that second calculation is where the partner’s comfort turns into the partner’s anxiety.
Consider what Novartis can see. It knows Arrowhead’s central nervous system platform would hand Lilly, already committed to Alzheimer’s with an approved drug, a delivery technology Lilly does not have. It knows Arrowhead’s obesity programs would give Lilly a differentiated complement to the most valuable weight-loss franchise in the industry. It knows, too, that Roche, which pioneered the brain-delivery science Arrowhead competes in, would treat losing Arrowhead to anyone as a strategic wound. Novartis, precisely because it understands the platform, understands that it is not the only one who will covet it, and that the others can bring resources Novartis has chosen not to match.
This is what converts Novartis’s patient, disciplined strategy into something more urgent. Left alone, Novartis might prefer to deepen the partnership gradually, license additional programs, and acquire only if and when the timing suited its cliff calendar. The presence of rivals removes that luxury. A partner who waits too long risks watching a better-funded competitor buy the company outright, taking not just a future asset but the existing partnership with it. The informed buyer’s knowledge, which makes it confident, is the same knowledge that tells it confidence is not safety.
This also answers the most obvious objection to the whole scenario. A skeptic could fairly point out that Novartis’s actual behavior toward Arrowhead has been to license, not to buy, and that its stated strategy favors small bolt-on deals over transformational acquisitions, so why assume it would ever acquire the entire company? The answer is precisely the foreclosure logic. Licensing works beautifully when no one else is bidding, because it lets Novartis acquire what it wants, one program at a time, at modest cost, while leaving the rest on the shelf. The moment a rival might buy the whole platform, that calm approach becomes a liability. A license secures one program but leaves the platform, and every future program it will generate, available for a competitor to take entirely. Against a serious rival bid, the disciplined licensing strategy stops protecting Novartis and starts exposing it, because the thing it most wants to keep out of a competitor’s hands is exactly the thing a license does not secure. This is the first appearance of a tension that runs through the whole trilogy, and that becomes decisive in the third paper: the strategies these companies prefer in calm conditions are the strategies that fail them in a contested one. The next paper introduces the rival whose resources Novartis most has reason to fear.
VII. How Arrowhead Plays It
From Arrowhead’s side of the table, an approach from Novartis is in some ways the most manageable of the three, precisely because the informed partner cannot lowball, and in one way the most delicate, because the existing relationship could be used to encourage a quiet, early deal before the platform’s full value is visible to the market.
Arrowhead’s central advantage, developed at length elsewhere in this series, is that it does not need to sell. It owns its manufacturing, it has an approved product and revenue, and it has a platform deep enough to fund its own future, which means it can decline any offer that fails to reflect the platform’s full value and simply continue building. Against Novartis specifically, that strength is amplified by the fact that Novartis cannot credibly argue the platform is worth little. The partner who has worked with the science and paid $12 billion for a cousin technology is in no position to plead ignorance of the value. Arrowhead can hold firm knowing its counterpart privately understands the platform as well as it does.
The sharper move available to Arrowhead is to make Novartis’s awareness of the other suitors work in Arrowhead’s favor. A company that can credibly continue alone, and that has more than one potential acquirer, is never obligated to accept a first mover’s terms. The mere fact that Lilly and Roche exist, and that Novartis knows they exist, raises the floor on what Novartis must offer to preempt them. Arrowhead does not need to orchestrate a bidding war to benefit from one being possible; the possibility alone disciplines the offer. The honest limit on this, which Arrowhead’s leadership would weigh seriously, is that an early, certain, generous offer from a trusted partner carries real value too, certainty and a known counterpart are worth something, and a credible offer that fairly reflects the platform’s value might rationally be accepted rather than gambled against an auction that may or may not materialize. The point is not that Arrowhead should refuse Novartis. It is that Arrowhead, holding a strong position and more than one option, sets the terms on which any conversation proceeds.
VIII. Conclusion: The Partner’s Dilemma
Novartis is the suitor that knows Arrowhead best, wants it for the most documented reasons, and has already proven, with the Avidity deal, that it will pay a price far beyond its stated discipline for exactly this kind of platform. On the surface, that makes Novartis the most natural acquirer of the three. Underneath, it makes Novartis the most exposed, because everything that lets it see Arrowhead’s value clearly also lets it see how much a rival would gain by taking it, and how little Novartis can do to stop a better-funded competitor from trying.
That is the partner’s dilemma, and it is where this first paper hands off to the second. Novartis would prefer to move on its own timetable, disciplined and patient, acquiring to fill its cliff when the moment is right. The trouble is that the moment may not be Novartis’s to choose. The deepest knowledge of the asset does not confer the deepest pockets, and the company that can simply outspend everyone is not the careful Swiss partner but the American giant flush with the proceeds of one of the most successful drug franchises the industry has ever seen. Novartis knows the value. The next suitor can pay it without blinking. What happens when the giant enters the board is the subject of Part Two.
The queen is under attack, and Novartis is the first to know it. “En garde” was always a courtesy, a warning offered to an opponent who might not yet have seen the danger. The irony of this trilogy is that no such courtesy will be extended here. Each player can see the queen, each knows the others can see it too, and none will wait politely for the rest to notice. Novartis hears the warning first because it stands closest to the board. It will not be the last to hear it.
A Note on Supporting Independent Research
If this white paper has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.
For individual investors and readers
Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.
For family offices, investment funds, hedge funds, and research platforms
This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,500 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.
There is no obligation and no expectation. This is purely a thank you for work that meant something to you.
Zelle: (847) 227-7909
Thank you for reading, and for being part of a community that takes this thesis seriously.
— Robert Toczycki | BioBoyScout
Important Risks, Disclosures, & Disclaimers
The author, Robert Toczycki (aka BioBoyScout), certifies that:
all views expressed in this white paper accurately reflect his personal opinions about the topic discussed;
he was not compensated in any form for producing this white paper; and
he has not received and does not receive compensation from Arrowhead Pharmaceuticals.
This paper is provided for informational and analytical purposes only. It is a strategic thought experiment based entirely on publicly available information, including company acquisition histories, public strategic statements, earnings disclosures, and trade press reporting, as of the date of publication. It does not constitute investment advice, financial advice, legal advice, or a recommendation to buy, sell, or hold any security, and it is not a recommendation as to any corporate course of action. It is not a prediction of any transaction, and the author has no knowledge of any actual deal discussions among any of the companies described. Scenarios involving how companies would behave are analytical interpretations grounded in documented past behavior, not statements of fact about any company’s intentions or any individual’s thinking. The author holds a long position in Arrowhead common stock. Past performance is not indicative of future results, and forward-looking analysis is inherently uncertain. The author and BioBoyScout are not registered investment advisors. The author assumes no obligation to update this paper.
About the Author
BioBoyScout is the publishing name for Robert Toczycki, an independent biotech investment research writer based in Chicago. The BioBoyScout series publishes institutional-grade analysis of structural dynamics in RNA-class therapeutics, with particular focus on Arrowhead Pharmaceuticals’ TRiM platform and the broader competitive landscape. Robert is a registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.
Comments or questions: bioboyscout@gmail.com.
Copyright © 2026, BioBoyScout. All Rights Reserved.
